CyGenica Ltd.

What We Do CyGenica uses a non-viral, non-toxic platform to develop in vitro and in vivo delivery solutions for drugs, gene editing components, and antibiotics. The most crucial issue of intracellular delivery for large molecules, especially for gene therapy, remains the cellular membrane. This biological barrier is a double-edged sword; while it prevents infectious agents from entering our body and causing disease, it also stands between the successful use of life-saving medicines and advanced therapeutic technologies. The successful delivery of therapeutics into target cells and organelles would minimize the undesired ‘off target’ side effects and reduce the required dose. Why We Do Our founder’s father was diagnosed with cancer when she was still a student. She witnessed her father suffering from the side effects of his therapy over years. This life experience defined the goal of her life 'how to make cancer drugs safer and better' to make an impact in oncology and do her bit in the global fight against cancer. CyGenica is the result of her and our team’s intense desire to make significant contributions to alleviate this suffering and improve the quality of life of millions of cancer patients. Who We Are We are a team of ambitious academicians and professionals striving to improve patient outcomes worldwide. Our goal is to develop the world's safest molecular carrier for therapeutics delivery and grow as an authentic market leader in enabling the next generation genome editing therapeutics for various life-threatening diseases such as cancer. With an indomitable spirit, we are committed to improve the quality of life of such patients.